Technical Analysis for BGNE - BeiGene, Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
133.27 | 5.34% | 6.75 |
BGNE closed up 5.34 percent on Thursday, October 17, 2019, on 61 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 5.34% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Humanized Antibody Oncogenes Lymphomas Ras Subfamily Braf Kras
Biopharmaceutical Cancers Monoclonal Antibodies Humanized Antibody Oncogenes Lymphomas Ras Subfamily Braf Kras
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BGNE news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 164.99 |
| 52 Week Low | 105.19 |
| Average Volume | 328,800 |
| 200-Day Moving Average | 130.8508 |
| 50-Day Moving Average | 132.019 |
| 20-Day Moving Average | 124.262 |
| 10-Day Moving Average | 121.771 |
| Average True Range | 4.8153 |
| ADX | 18.44 |
| +DI | 30.4735 |
| -DI | 20.1223 |
| Chandelier Exit (Long, 3 ATRs ) | 123.4141 |
| Chandelier Exit (Short, 3 ATRs ) | 128.9659 |
| Upper Bollinger Band | 136.5903 |
| Lower Bollinger Band | 111.9337 |
| Percent B (%b) | 0.87 |
| BandWidth | 19.84243 |
| MACD Line | -1.6996 |
| MACD Signal Line | -3.198 |
| MACD Histogram | 1.4984 |
| Fundamentals | Value |
|---|---|
| Market Cap | 5.31 Billion |
| Num Shares | 39.8 Million |
| EPS | -4.97 |
| Price-to-Earnings (P/E) Ratio | -26.81 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 12.46 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 142.29 | ||||
| Resistance 3 (R3) | 141.39 | 137.48 | 140.78 | ||
| Resistance 2 (R2) | 137.48 | 135.19 | 137.93 | 140.28 | |
| Resistance 1 (R1) | 135.38 | 133.77 | 136.43 | 136.28 | 139.78 |
| Pivot Point | 131.47 | 131.47 | 132.00 | 131.92 | 131.47 |
| Support 1 (S1) | 129.37 | 129.18 | 130.42 | 130.27 | 126.76 |
| Support 2 (S2) | 125.46 | 127.76 | 125.91 | 126.26 | |
| Support 3 (S3) | 123.36 | 125.46 | 125.76 | ||
| Support 4 (S4) | 124.26 |
